Although the viral markers hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HbcrAg) could reflect intrahepatic hepatitis B virus (HBV) replication activity and constitute important biomarkers for hepatocellular carcinoma (HCC), the value of using these two markers in combination for assessing HCC risk has not been clarified in detail.
Although~90% of cases achieve hepatitis B e antigen (HBeAg) seroconversion and become inactive carriers, active hepatitis persists in the remaining 10% of cases 2 and antiviral therapies such as nucleot(s)ide analogues (NAs) are generally needed. Nucleot(s)ide analogues suppress hepatitis B virus (HBV)-DNA synthesis and inactivate hepatitis, however, it has become gradually evident that NA therapy cannot completely eliminate and inhibit the development of hepatocellular carcinoma (HCC). 3 Serum HBV-DNA titer, which had been the most important biomarker for assessing the risk of HCC development, 4, 5 is no longer useful as NAs suppress HBV-DNA, therefore accurate biomarkers to predict HCC development, other than HBV-DNA, are urgently needed.
One of the reasons for HCC development under NA therapy is the difficulty of these agents to eradicate HBVcovalently circular closed DNA (HBV-cccDNA) in the liver. 6 Specifically, these NAs only inhibit reverse transcription of HBV-RNA into HBV-DNA and do not directly inhibit transcription and subsequent protein synthesis from HBV-cccDNA. 7 Because the quantity and transcriptional activity of intrahepatic HBV-cccDNA is considered to affect the incidence of HBV-induced HCC under NA therapy, 8 quantification of intrahepatic HBV-cccDNA should be an important marker for predicting HCC. However, the quantification of HBV-cccDNA requires an invasive liver biopsy.
Non-invasive surrogate markers of quantitative hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) assays have been developed recently. 9, 10 To date, HBsAg and HBcrAg have been investigated separately for their association and predictability for HCC development, but the correlations of these two markers for HCC development are still limited and controversial. Considering the different dynamics of these two markers in the HBV life cycle, we hypothesized that combining these two markers, rather than using them separately, might help in extracting the patients with HCC risk.
In this study, cross-sectional and longitudinal analyses were carried out in order to determine the value of HBsAg and HBcrAg in combination for the association of HCC development.
METHODS

Patients
A MONG ALL HBV-INFECTED patients who visited the Yamanashi University Hospital (Chuo, Japan) from 2000 to 2015 for their HBV-related liver disease, the 449 consecutive patients who met the following criteria were included in the study (Fig. 1 ). Patients were required to be available for evaluation of HBsAg, HBcrAg, HBeAg, anti-HBe, and HBV-DNA, laboratory data, and imaging studies at least once during the follow-up period. Patients with acute hepatitis and reactivation or co-infection with hepatitis C virus and/or HIV were excluded. To clarify the value of simultaneous measurement of HBsAg and HBcrAg for the association with history of HCC and future HCC development, the oldest simultaneous measurement data of HBsAg and HBcrAg after 2009 were used for the crosssectional analysis as well as for the longitudinal analysis.
The study protocol conformed to the ethical guidelines of the 2000 Declaration of Helsinki and consent was Figure 1 Flowchart of the study design. In examination 1 (cross-sectional study), 449 patients were divided into two groups according to their history of hepatocellular carcinoma (HCC), and clinical characteristics were investigated. In examination 2 (longitudinal study), 338 patients without a history of HCC at the time of the crosssectional study were observed longitudinally for HCC occurrence for up to 5 years. HBeAg, hepatitis B e antigen; HCV, hepatitis C virus. obtained for participation in the study, which had been approved by the Human Ethics Review Committee of Yamanashi University.
Measurement of HBsAg and HBcrAg, and definition of HCC
Serum HBsAg was measured quantitatively by the chemiluminescent immunoassay method using ARCHITECT (Abbot, Tokyo, Japan). In this study, the cut-off value of HBsAg in the association with HCC was determined to be 1000 IU/mL (3.0 log IU/mL) according to a previous study.
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Serum HBcrAg was quantitatively measured by LUMIPULSE (Fujirebio, Tokyo, Japan), and the cut-off value of HBcrAg associated with HCC was also determined to be 3.0 log U/mL.
The presence of HCC was defined as follows: imaging of tumors found to be HCC-specific in at least two of four imaging studies using abdominal ultrasound, contrast medium-enhanced dynamic computed tomography, contrast medium-enhanced magnetic resonance imaging, and computed tomography angiography. In addition, HCCs were also diagnosed following pathological investigation.
Cross-sectional study (examination 1)
In the first cross-sectional analysis, 449 patients were divided according to HCC history (including past and present HCCs) and the influence of the two markers (HBsAg and HBcrAg) on HCC history was investigated using clinical laboratory, imaging, and pathological studies. As a result, the HCC history (+) group comprised 81 patients and the HCC history (À) group comprised 368 patients (Fig. 1 ).
Longitudinal study (examination 2)
Following examination 1, the influence of HBsAg and HBcrAg on future HCC occurrence was investigated longitudinally for the 368 patients without HCC at entry. In order to clarify the future influence of the two markers, individuals observed for more than 6 months (maximum of 5 years) were included in this study. As a result, 338 patients were included; new HCC developed in 14, and HCC did not develop in 324 (Fig. 1 ).
Statistical analysis
Statistical differences in the parameters, including all available demographic, biochemical, hematological, and virological variables, were determined for the various patient groups by Fisher's exact probability test for categorical variables. The odds ratios and 95% confidence intervals were calculated. Kaplan-Meier curves were drawn and the logrank test was applied. Logistic regression analysis and the Cox proportional hazards analysis were used for multivariate analyses. P-values of <0.05 by the two-tailed test were considered to indicate statistical significance. 
RESULTS
Background characteristics of patients
T HE BACKGROUND CLINICAL characteristics of the patients are shown in Table 1 , grouped according to NA therapy at the time of enrollment. Nucleos(t)ide analogues had been started in 33% (149/449) of the patients. Characteristics in these two groups were rather different: in the NA group, older age, male sex, genotype C, low serum HBV-DNA, anti-HBeAg, high HBcrAg, low platelet count, and HCC history were more frequent. History of HCC was observed in 35% (52/149) of the NA group and in 10% (29/300) of non-NA group.
Cross-sectional study (examination 1)
Clinical characteristics of patients according to HBsAg/HBcrAg titer To determine the correlation between HBsAg/HBcrAg titers and HCC history, the distribution of patients with HCC history according to HBsAg/HBcrAg titer was investigated. As shown in Figure 2 , when these patients with HCC history were stratified by HBsAg or HBcrAg titers, they were found more frequently in the low HBsAg group (<3.0 log IU/mL) and in the high HBcrAg group (≥3.0 log U/mL).
To investigate the clinical features further, the patients were grouped according to their HBsAg/HBcrAg titers, and their clinical variables were subjected to univariate analyses. The characteristics of the low HBsAg group were as follows: elderly (P < 0.001), male sex (P = 0.006), low aspartate aminotransferase (AST) (P = 0.042), low alanine aminotransferase (ALT) (P = 0.001), low platelet count (P = 0.031), HBeAg negative (P < 0.001), and HCC history (P < 0.001) ( Table 2 ). In the multivariate analysis, elderly (P < 0.001), male sex (P = 0.015), and HBeAg negative (P < 0.001) were extracted as independent factors related to low HBsAg titer. In the high HBcrAg group, younger age (P < 0.001), high total bilirubin (T-Bil) (P = 0.005), low albumin (Alb) (P = 0.008), high AST (P < 0.001), high ALT (P < 0.001), high γ-glutamyltransferase (γGTP) (P < 0.001), low platelet count (P < 0.001), NA therapy (P < 0.001), and HCC history (P < 0.001) were characteristic (Table 2 ). In the multivariate analysis, younger age (P < 0.001), low Alb (P = 0.008), high ALT (P = 0.005), NA therapy (P < 0.001), and HCC history (P < 0.001) were extracted as independent variables.
Factors associated with history of HCC
Next, we examined the factors contributing to HCC history. In the univariate analysis, older age (P < 0.001), male sex (P = 0.001), high T-Bil (P = 0.018), high γ-GTP Figure 2 Association between hepatitis B surface antigen (HBsAg)/hepatitis B core-related antigen (HBcrAg) titers and the distribution among those with history of hepatocellular carcinoma. (a) HCC history was significantly frequent in the low HBsAg group. When the patients were divided into two groups according to the HBsAg cut-off of 3.0 log IU/mL, those with an HCC history were significantly frequent in the low HBsAg group (P < 0.001). (b) HCC history was significantly frequent in high HBcrAg group. When the patients were divided into two groups according to the HBcrAg cut-off of 3.0 log U/mL, those with an HCC history were significantly frequent in the high HBcrAg group (P < 0.001). 
<0.001
There was no multicollinearity among variables of age, platelet count, HBsAg, or HBcrAg.
†Data are shown as average values or n (%). γGTP, γ-glutamyltransferase; Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; HBeAg, hepatitis B e antigen; HCC, hepatocellular carcinoma; NA, nucleos(t) ide analogue; OR, odds ratio; T-Bil, total bilirubin.
-, It was not included in the analysis.
HBsAg and HBcrAg in HCC risk assessment 55 Hepatology Research 2019; 49: 51-63 (P < 0.001), low platelet count (P < 0.001), low HBV-DNA (P < 0.001), low HBsAg (P < 0.001), high HBcrAg (P < 0.001), and NA treatment history (P < 0.001) were extracted (Table 3 ). In the multivariate analysis, older age (P < 0.001), high γGTP (P = 0.029), low platelet count (P < 0.001), low HBsAg (P = 0.002), high HBcrAg (P < 0.001), and NA therapy (P = 0.032) were independent.
Factors associated with HCC history were further investigated after dividing the patients into two groups according to NA therapy. In the multivariate analysis, older age (P = 0.045), low platelet count (P = 0.002), and low HBsAg (P = 0.022) were independent in the NA group (Table 4a) , whereas older age (P < 0.001), low platelet count (P = 0.004), and high HBcrAg (P < 0.001) were independent in the non-NA group (Table 4b) . However, in the analysis of the non-NA group (Table 4b) , the number of variables (n = 5) was too large to obtain the most stable result considering the number of patients with HCC history (n = 29). Therefore, we added the analysis after decreasing the number of variables with the variable selection (forward selection) method (Table S1 ). In this re-analysis, older age (P < 0.001), low platelet count (P = 0.001), and high HBcrAg (P < 0.001) were also independent factors.
Hepatitis B surface antigen/HBcrAg and HCC history: Subclass analysis
The relationships among HCC history, HBsAg, and HBcrAg were further investigated by subclass analyses.
The patients were divided into four categories according to HBsAg and HBcrAg titers using the cut-off values. Analyses were undertaken on all patients, NA-treated patients, and NA-free patients.
Among the 449 patients (Fig. 3a) , HCC history was most frequent in those with low HBsAg and high HBcrAg (group D, 51.7%) in HBeAg-negative patients (group A vs. group D: OR, 32.27, P < 0.001; group B vs. group D: OR, 5.92, P < 0.001; group C vs. group D: OR, 6.33, P < 0.001; group ABC vs. group D: OR, 7.83, P < 0.001). In HBeAg-positive patients, there was also a tendency that HCC history was more frequent in those with low HBsAg/high HBcrAg (group F, 34.8% vs. group E, 15.1%: OR, 2.99, P = 0.07).
Among the 149 patients treated with NAs ( Fig. 3b) , HCC history was also most common in those with low HBsAg and high HBcrAg in the HBeAg-negative (group D, 61.8%) patients (group A vs. group D: OR, 17.77, P < 0.001; group B vs. group D: OR, 5.08, P = 0.003; group C vs. group D: OR, 3.23, P = 0.023; group ABC vs. group D: OR, 4.76, P < 0.001). In HBeAg-positive patients, there was also a tendency that HCC history was rather frequent in those with low HBsAg/high HBcrAg (group F, 38.5% vs. group E, 25.8%; P = 0.48).
In the Figure 3(b) analysis, patients who started NA therapy after the onset of HCC were included. To evaluate the influence of NA usage on the development of past HCC, exclusion of those patients was needed. Therefore, in Figure 3 (c), patients without HCC at the start of NA therapy were analyzed. In this analysis (Fig. 3c) , HCC history was also most frequent in group D (group A vs. group D: OR, could not be calculated, P = 0.018; group B vs. group D: OR, 3.38, P = 0.076; group C vs. group D: OR, 6.15, P = 0.024; group ABC vs. group D: OR, 5.45, P = 0.004).
Similarly, in 300 patients without NA treatment (Fig. 3d) , HCC history was most frequent in those with low HBsAg and high HBcrAg (group D, 38.5%; group F, 30%) (group A vs. group D: OR, 36.25, P < 0.001; group B vs. group D: OR, 10.94, P = 0.001; group C vs. group D: OR, 6.93, P < 0.001; group ABC vs. group D: OR, 9.60, P < 0.001). In HBeAg-positive patients, there was a tendency that HCC history was frequent in those with low HBsAg and high HBcrAg (group F, 30.0% vs. group E, 5.7%; OR, 7.07, P = 0.07).
Clinical characteristics of the patients according to HBsAg and HBcrAg titers were further investigated (Table 5) . In group D, older age, high γGTP, low platelet count, low HBV-DNA, and NA therapy were more frequent. In Figure 4 , all cases were plotted as differentcolored dots depending on the presence of HCC history. <0.001 †Data shown as average values or n (%). γGTP, γ-glutamyltransferase; Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; OR, odds ratio; T-Bil, total bilirubin. -, It was not included in the analysis.
To draw the scatter plots, patients were further divided according to HBeAg positivity, because HBeAg, being a constituent of HBcrAg, could influence the result.
Longitudinal study (examination 2)
Contributory factors of future HCC occurrence: Univariate and multivariate analyses Next, among 368 patients without HCC at study entry, the longitudinal occurrence of new HCC was investigated in 338 patients, observed for more than 6 months. The 3-year cumulative HCC occurrence rate was 2.7%, and the 5-year cumulative rate was 5.2%. In univariate analysis using the log-rank test, high cumulative HCC occurrence was observed in patients who were elderly (P < 0.001), male (P = 0.014), with a low platelet count (P = 0.006), and allocated to group D (high HBcrAg/low HBsAg group in HBeAg-negative patients, P = 0.006) ( Table 6 ). A multivariate analysis using the Cox proportional hazard model revealed that older age (hazard ratio [HR], 3.47; 95% confidence interval [CI], 1.17-10.30; P = 0.025) and group D (HR, 3.58; 95% CI, 1.12-11.47; P = 0.032) were independent risks of HCC (Table 5 ). In this multivariate analysis, however, the number of variables (n = 5) was too large to obtain a statistically stable result as HCC occurred only in 14 patients. Therefore, we added the analysis after decreasing the number of variables with the variable selection (forward selection) method (Table S2) . In this analysis, older age (HR, 4.73; 95% CI, 1.63-13.70; P = 0.004) and group D (HR, 3.58; 95% CI, 1.25-12.78; P = 0.020) were also independent. (14) 21 (13) 31 (52) 10 (15) 8 (35) <0.001 <0.001 †Data are shown as average values or n (%). γGTP, γ-glutamyltransferase; Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen; HCC, hepatocellular carcinoma; NA, nucleos(t) ide analogue; T-Bil, total bilirubin. To further clarify the association of each HBsAg/HBcrAg subset for the cumulative HCC occurrence, Kaplan-Meier curves were drawn in each HBsAg/HBcrAg subset (Fig. 5a ). Significant difference from group D (low HBsAg/high HBcrAg in HBeAg-negative patients) was observed with group A (high HBsAg/low HBcrAg in HBeAg-negative patients, P = 0.009), group C (low HBsAg/low HBcrAg in HBeAg-negative patients, P = 0.042), and group E (high HBsAg/high HBcrAg in HBeAg-positive patients, P = 0.021). Through the comparison between group D and C, it was shown that HCC occurrence in patients with low HBsAg titer was significantly influenced and upregulated by high HBcrAg titer. Hepatocellular carcinoma occurrence in group D patients was higher when compared with non-group D (ABCEF, P = 0.005) (Fig. 5b) .
Because NA therapy is an intervention factor influencing the clinical course, the cumulative HCC occurrence was further investigated separately, depending on the usage of NA therapy (at least 6 months). The cumulative HCC occurrence rate tended to be higher in group D patients with NA treatment (P = 0.140), and was significantly high in group D patients without NA treatment (P = 0.008) (Fig. 5c,d) .
DISCUSSION
I N THIS STUDY, focusing on the recently developed intrahepatic HBV cccDNA surrogate markers, serum quantitative HBsAg and HBcrAg, we showed that the subset of patients with low HBsAg/high HBcrAg had a high association with HCC history, by cross-sectional analysis.
Moreover, we found that the subset of patients with low HBsAg/high HBcrAg had a high risk of developing HCC in the future by longitudinal analysis.
Hepatitis B surface antigen is a classical viral marker but a recently advanced measuring technique has enabled quantitative HBsAg evaluation. Because HBV protein production reflects the activity of potential intrahepatic viral replication and transcription from intrahepatic HBVcccDNA, and is not influenced by NA therapy, the serum HBsAg titer could be an important marker for assessing viral activity during NA therapy. Actually, serum HBsAg reflects the intrahepatic HBV-cccDNA level. 9 However, the correlation between HBsAg and advancing liver disease and HCC occurrence is rather complicated: several studies undertaken so far reported a trend for lower HBsAg levels in cirrhosis, contrary to expectation. 12, 13 Although the precise mechanism is unclear, one reason for serum HBsAg decrease might be a result of natural HBsAg clearance, reflecting intrahepatic HBV-cccDNA decrease induced by elimination of HBV-infected hepatocytes during the immune-elimination phase. Another reason might be a result of HBsAg excretion disorder from hepatocytes induced by preS/S mutations in the HBV genome.
14 Namely, preS/S mutations are known to occur in order to escape from the host's immune attack, but those preS/S mutants cause an imbalance of surface protein synthesis resulting in intracellular accumulation and extracellular decrease of HBsAg proteins. 15 In our observation, patients with preS/S mutations tended to have a lower serum HBsAg titer while they had advanced liver diseases, including HCC (Y. Suzuki, S. Maekawa, N. Komatsu, M. Sato, A. 16 Because these proteins are products of the precore/core gene transcripts, which are considered not to be influenced by NA therapy, 17 HBcrAg could be another appropriate candidate for assessing viral replication activity during NA therapy. Of note, correlation with cccDNA was also reported for HBcrAg. 10 As with HBsAg, the HBcrAg assay was reported to be of value as a predictor for the safe termination of NA therapy, because HBcrAg clearance might reflect the clearance of intrahepatic HBV-cccDNA. [18] [19] [20] Importantly, because HBcrAg is not affected by preS/S variants, HBcrAg could be a more suitable, representative marker of intrahepatic viral replication activity than HBsAg. Contrary to the inverse association between liver disease advancement/HCC and HBsAg, the association of liver disease advancement/HCC occurrence and HBcrAg is positive. 11, 21 Recently, Kumada et al. reported that the serum HBcrAg level and mutations in the basal core promoter are independent risk factors of HCC. 22 Our data also show that the proportion of patients with HCC increases when stratified by increasing HBcrAg titer (Fig. 2b) .
Considering the behavior of HBcrAg, the combination of HBsAg and HBcrAg could be a useful method to discriminate the presence or absence of active viral replication in patients with low HBsAg. In accordance with this hypothesis, we have reported that the subset of patients with low HBsAg/high HBcrAg (group D) had the highest proportion of individuals with an HCC history, according to the cross-sectional analysis (Fig. 3) . We have also shown that HBcrAg would be a suitable marker discriminating the HCC developmental risk among patients with low HBsAg ( Fig. 5a ; C vs. D, P = 0.042) in the longitudinal analysis, suggesting the validity of the hypothesis. When patients were divided into two groups (D vs. ABCEF) to extract the characteristics of the subset of group D, it was shown that group D had a higher risk of developing HCCs (Fig. 5b) . Importantly, the proportion with an HCC history was high in group D irrespective of the introduction of NA therapy in the cross-sectional study (Fig. 3) . In the longitudinal study, new HCC development was also high irrespective of NA therapy (although those with NA therapy did not reach statistical significance), illustrating the importance of assessing HCC risk by the HBsAg /HBcrAg combination. When we classified clinical characteristics of patients according to the combination of HBsAg/HBcrAg titers, HCC high risks such as older age and low platelet count (= fibrosis) were found to be accumulated in the group D subset (Table 5) . Importantly, we could show that group D was associated with HCC independent of the variables of older age and/or low platelet count. It also illustrated the importance of assessing HCC risk with the HBsAg/HBcrAg combination (Tables 3,4,6).
In this study, it is our basic hypothesis that the hepatocytes with active intracellular HBV replication even under NA therapy have the potential to develop HCCs. If this is so, what is the difference between high HBsAg/high HBcrAg and low HBsAg/high HBcrAg for the role of HCC occurrence? As described previously, the situation of low HBsAg under high HBcrAg might reflect the existence of preS/S variants occurring as the result of immune escape. These preS/S variants are known to have a close relation with HCC development, possibly because intracellular endoplasmic reticulum (ER) HBsAg accumulation leads to ER stress-dependent and ER stress-independent hepatocarcinogenesis. 14, 15 However, such a hypothesis should be further studied and confirmed in future analyses.
Contrary to our study, some previous studies reported that HCC risk was elevated as HBsAg titer increased. 23, 24 However, in these studies, most patients had genotype B HBV, and HCC risk elevation was observed only in a specific cohort of patients with low HBV-DNA load of <1000 IU/mL. As serum HBs antigen decrease caused by preS/S mutations for escaping from immune cells does not likely to occur in low immunogenic hepatocytes with low HBV replication capacity and/or with genotype B HBV, 25, 26 serum HBsAg titer might directly reflect intrahepatic HBV-cccDNA activity in those patients. If this is so, positive correlation between HBsAg and HCC risk is plausible in those conditions, and the result is not contradictory to our study. Further studies are needed.
In conclusion, it was found that the low HBsAg/high HBcrAg value patient group is at high risk for HBV-related HCC according to cross-sectional and longitudinal analyses, indicating that the combination of HBsAg and HBcrAg values is an excellent biomarker for assessing HCC risk in the era of NA therapy, where HBV-DNA cannot be measured.
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